A Novel Approach in Solid Tumors: Updates on Alpha Tau’s Recent and Upcoming Alpha DaRT Trials
About The Event
Join us for the Hybrid Alpha Tau KOL Breakfast Event, which will feature presentations from Key Opinion Leaders (KOLs) Michael J. Zelefsky, MD (Memorial Sloan Kettering Cancer Center), Mark D’Andrea, MD (University Cancer Centers) and Robert Den, MD (Alpha Tau’s Chief Medical Officer) who will discuss the science behind Alpha Tau’s therapy (the Alpha DaRT radiation technology) and its clinical trial outlook.
The Alpha DaRT technology is based on small amounts of radioactive radium-224 affixed to metal sources that are inserted into the tumor itself, which are designed to decay and release radioactive atoms, with short lifespans, that diffuse inside the tumor, emitting short-range alpha radiation that aims to damage and kill cancer cells within a short period of time.
During the KOL presentations, Alpha Tau’s recent clinical trials, upcoming U.S. pivotal trial in recurrent cutaneous Squamous Cell Carcinoma (SCC), other upcoming clinical trials, and their pre-clinical work on potential immunological effects of the Alpha DaRT technology will be discussed.
A Q&A session will follow the formal presentations.